ClinicalTrials.Veeva
Menu

Find clinical trials for Colon Cancer in Seattle, WA

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Colorectal Cancer
Colonic Cancer
Cancer
Non-Small-Cell Lung Carcinoma
Lung Cancer
Neoplasm Metastasis
Adenocarcinoma

Colon Cancer trials near Seattle, WA, USA:

PhII Trial Panitumumab, Nivolumab, Ipilimumab in Kras/Nras/BRAF Wild-type MSS Refractory mCRC

with panitumumab in subjects with unresectable, refractory, KRAS/NRAS/BRAF wild-type, microsatellite stable (MSS) metastatic colorectal cancer...

Active, not recruiting
Colon Cancer
Drug: Nivolumab
Drug: Ipilimumab

Phase 2

UNC Lineberger Comprehensive Cancer Center
UNC Lineberger Comprehensive Cancer Center

Seattle, Washington, United States and 4 other locations

(PK) of BBO-8520, a KRAS G12C (ON) inhibitor, single agent and in combination with pembrolizumab in patients with advanced non-small cell lung cancer...

Enrolling
Colon Cancer
Metastatic Colon Cancer
Drug: BBO-8520
Drug: Pembrolizumab

Phase 1

TheRas, Inc., d/b/a BridgeBio Oncology Therapeutics

Seattle, Washington, United States and 14 other locations

To confirm the safety and performance of the da Vinci SP Surgical System, Instruments and Accessories in a complex colorectal procedure such as low a...

Active, not recruiting
Benign or Malignant Rectal or Colon Tumors
Colorectal Cancer
Device: Robotic Assisted Surgery
Intuitive Surgical
Intuitive Surgical

Tacoma, Washington, United States and 8 other locations

oral LOXO-292 in pediatric participants with an activating rearranged during transfection (RET) alteration and an advanced solid or primary CNS tumor...

Enrolling
Papillary Thyroid Cancer
Medullary Thyroid Cancer
Drug: LOXO-292

Phase 1, Phase 2

Loxo Oncology
Loxo Oncology

Seattle, Washington, United States and 25 other locations

This Phase II/III trial will evaluate the what kind of chemotherapy to recommend to patients based on the presence or absences of circulating tumor...

Enrolling
Stage III Colon Cancer
Drug: mFOLFOX6 3-6 month
Device: Signatera test

Phase 2, Phase 3

NRG Oncology
NRG Oncology

Seattle, Washington, United States and 904 other locations

known as MVC-101) in adults with unremovable advanced or metastatic cancer. Another aim is to characterize and evaluate the activity of TAK-...

Enrolling
Non-small Cell Lung Cancer (NSCLC)
Squamous Cell Cancer of Head and Neck (SCCHN)
Drug: TAK-186

Phase 1, Phase 2

Takeda
Takeda

Seattle, Washington, United States and 22 other locations

plus BSC in participants with refractory metastatic colorectal cancer (mCRC). 691 participants were randomized to one of the following treat...

Active, not recruiting
Metastatic Colorectal Cancer
Metastatic Colon Cancer
Drug: Fruquintinib
Drug: Placebo

Phase 3

HUTCHMED
HUTCHMED

Everett, Washington, United States and 152 other locations

The goal of this study is to test A2B694, an autologous logic-gated Tmod™ CAR T-cell product in subjects with solid tumors including colorec...

Enrolling
Ovarian Neoplasms
Solid Tumor, Adult
Diagnostic Test: xT CDx with HLA-LOH Assay
Biological: A2B694

Phase 1, Phase 2

A2 Biotherapeutics

Seattle, Washington, United States and 9 other locations

evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 (adagrasib) in patients with advanced solid tumors...

Enrolling
Metastatic Cancer
Advanced Cancer
Drug: Cetuximab
Drug: Afatinib

Phase 1, Phase 2

Mirati Therapeutics
Mirati Therapeutics

Seattle, Washington, United States of America and 219 other locations

of RO7198457 versus watchful waiting in patients with circulating tumor DNA (ctDNA) positive, surgically resected Stage II/III rectal cancer...

Enrolling
Colorectal Cancer Stage III
Colorectal Cancer Stage II
Drug: RO7198457 intravenous (IV)
Other: Observational group (no intervention)

Phase 2

BioNTech
BioNTech

Seattle, Washington, United States and 117 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems